|
See related Konakion MM information |
|
|
|
Manufacturer |
Roche |
|
Distributor |
DKSH |
|
Contents |
Phytomenadione (vit K1) |
|
Indications |
Hemorrhage or threatened hemorrhage during severe hypoprothrombinemia. Prophylaxis & treatment of hemorrhage in newborns. |
|
Dosage |
Amp Severe or life-threatening hemorrhage 5-10 mg IV together w/ fresh frozen plasma or prothrombin. Ped amp Prophylaxis of hemorrhage in the newborn 2 mg orally at birth followed by 2 mg at days 4-7. Therapy Initially 1 mg IV & further doses as needed depending on clinical picture. |
|
Adverse Drug Reactions |
Rarely, severe shock-like reactions, phlebitis, inj site irritation, immune system disorders.
View ADR Monitoring Form |
|
Drug Interactions |
Coumarin-type anticoagulants.
View more drug interactions with Konakion MM |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Konakion MM injection |
|
Konakion MM 10 mg/1 mL x 5's |
|
|
Konakion MM ped injection |
|
Konakion MM 2 mg/0.2 mL x 5's |
|
|
|
Manufacturer: |
Roche |
|
Distributor: |
DKSH |
|
|
|
